Enveric Biosciences, Inc.

For the period ended Jun 30, 2026. Filed Aug 14, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2026 · Filed Aug 14, 2026

ENVB$1.42+1.7%Stored close · as of Nov 6, 2026

See the whole filing, with its images and exhibits

Contents

Item 1. Condensed Consolidated Balance Sheets as of June 30, 2026 (Unaudited) and December 31, 2025

CONDENSED CONSOLIDATED BALANCE SHEETS

	June 30, 2026	December 31, 2025
(Unaudited)
ASSETS
Current assets:
Cash	$8,296,296	$4,677,491
Prepaid expenses and other current assets	497,029	259,216
Total current assets	8,793,325	4,936,707
Other assets:
Property and equipment, net	81,929	159,234
Deferred offering costs, non-current	68,745	—
Total other assets	150,674	159,234
Total assets	$8,943,999	$5,095,941
LIABILITIES, MEZZANINE EQUITY, AND SHAREHOLDERS’ EQUITY
Current liabilities:
Accounts payable	$682,794	$581,020
Due to related parties	26,750	99,875
Accrued expenses and other current liabilities	151,931	237,505
Total current liabilities	861,475	918,400
Commitments and contingencies (Note 9)	-	-
Mezzanine equity
Series C redeemable preferred stock, $0.01 par value, 100,000 shares authorized, and 0 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively	—	—
Total mezzanine equity	—	—
Shareholders’ equity
Preferred stock, $0.01 par value, 20,000,000 shares authorized; Series B preferred stock, $0.01 par value, 3,600,000 shares authorized, 0 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively	—	—
Common Stock, $0.01 par value, 100,000,000 shares authorized, 3,935,884 and 1,061,533 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively	39,358	10,615
Additional paid-in capital	128,145,545	119,593,456
Accumulated deficit	(119,507,698)	(114,846,492)
Accumulated other comprehensive loss	(594,681)	(580,038)
Total shareholders’ equity	8,082,524	4,177,541
Total liabilities, mezzanine equity, and shareholders’ equity	$8,943,999	$5,095,941

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

	For the Three Months Ended June 30,		For the Six Months Ended June 30,
	2026	2025	2026	2025
Operating expenses
General and administrative	$1,635,478	$1,219,018	$2,885,439	$2,579,156
Research and development	1,355,137	1,260,051	1,701,106	2,006,422
Depreciation and amortization	36,826	39,980	74,066	121,004
Total operating expenses	3,027,441	2,519,049	4,660,611	4,706,582
Loss from operations	(3,027,441)	(2,519,049)	(4,660,611)	(4,706,582)
Other (expense) income
Other income	—	—	—	2,565
Interest (expense) income, net	(292)	(132)	(595)	(130)
Total other (expense) income	(292)	(132)	(595)	2,435
Net loss before income taxes	(3,027,733)	(2,519,181)	(4,661,206)	(4,704,147)
Income tax expense	—	—	—	—
Net loss	$(3,027,733)	$(2,519,181)	$(4,661,206)	$(4,704,147)
Other comprehensive loss
Foreign currency translation	(7,625)	24,473	(14,643)	20,986
Comprehensive loss	$(3,035,358)	$(2,494,708)	$(4,675,849)	$(4,683,161)
Net loss per share - basic and diluted	$(0.76)	$(11.65)	$(1.70)	$(25.76)
Weighted average shares outstanding, basic and diluted	3,987,084	216,311	2,743,993	182,590

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS’ EQUITY

Common Stock · Additional Paid-In · Accumulated · Accumulated Other Comprehensive · Total Shareholders’
	Shares	Amount	Capital	Deficit	Loss	Equity
Balance at January 1, 2026	1,061,533	$10,615	$119,593,456	$(114,846,492)	$(580,038)	$4,177,541
Issuance of Common Stock and warrants in Private Placement, net of offering costs of $368,990	328,802	3,288	1,140,739	—	—	1,144,027
Issuance of Common Stock for cash pursuant to ATM Agreement, net of offering costs of $54,484	497,200	4,972	1,286,066	—	—	1,291,038
Stock based compensation	—	—	88,673	—	—	88,673
Foreign exchange translation loss	—	—	—	—	(7,018)	(7,018)
Net loss	—	—	—	(1,633,473)	—	(1,633,473)
Balance at March 31, 2026	1,887,535	$18,875	$122,108,934	$(116,479,965)	$(587,056)	$5,060,788
Issuance of Common Stock and warrants in Private Placement, net of offering costs of $814,085	98,000	980	4,407,758	—	—	4,408,738
Exercise of warrants	1,950,349	19,503	1,503,739	—	—	1,523,242
Stock based compensation	—	—	125,114	—	—	125,114
Foreign exchange translation loss	—	—	—	—	(7,625)	(7,625)
Net loss	—	—	—	(3,027,733)	—	(3,027,733)
Balance at June 30, 2026	3,935,884	$39,358	$128,145,545	$(119,507,698)	$(594,681)	$8,082,524

Common Stock · Additional Paid-In · Accumulated · Accumulated Other Comprehensive · Total Shareholders’
	Shares	Amount	Capital	Deficit	Loss	Equity
Balance at January 1, 2025	56,501	$565	$108,261,264	$(106,074,505)	$(594,517)	$1,592,807
Issuance of Common Stock and Series A and B and prefunded warrants for cash, net of offering costs of $755,487	102,444	1,024	4,243,443	—	—	4,244,467
Issuance of common shares for vested RSAs	1,215	12	(12)	—	—	-
Issuance of common shares for exercise of warrants	38,528	385	74,659	—	—	75,044
Issuance of round up shares	7,283	73	(73)	—	—	-
Stock based compensation	—	—	193,848	—	—	193,848
Foreign exchange translation loss	—	—	—	—	(3,487)	(3,487)
Net loss	—	—	—	(2,184,966)	—	(2,184,966)
Balance at March 31, 2025	205,971	$2,059	$112,773,129	$(108,259,471)	$(598,004)	$3,917,713
Issuance of common shares for cash pursuant to ATM Agreement, net of offering costs of $179,714	46,197	462	555,042	—	—	555,504
Stock based compensation	—	—	206,260	—	—	206,260
Foreign exchange translation gain	—	—	—	—	24,473	24,473
Net loss	—	—	—	(2,519,181)	—	(2,519,181)
Balance at June 30, 2025	252,168	$2,521	$113,534,431	$(110,778,652)	$(573,531)	$2,184,769

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.